Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative)

v3.23.3
Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Research And Development Expenses $ 4,650,658 $ 4,002,212 $ 15,007,623 $ 11,202,902  
Terms of license Agreement     Belgian Volition received an upfront payment of $10.0 million in 2022, and is eligible to receive further milestone payments of (i) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC screening test for Canine Lymphoma & HSA, (ii) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC monitoring test for the same conditions, and (iii) $5.0 million upon the first commercial sale by or on behalf of Heska of a screening or monitoring test for lymphoma in felines    
Cash and cash equivalents 10,808,747   $ 10,808,747   $ 10,867,050
Accounts receivable $ 34,441   $ 34,441   $ 72,609
Warrants And Options [Member]          
Potentially Dilutive Securities Excluded From The Computation Of Eps 9,151,605   9,151,605    
Cash and cash equivalent [Member]          
Cash and cash equivalents $ 10,800,000   $ 10,800,000    
Research And Development Expenses [Member]          
Research And Development Expenses     $ 15,000,000.0 $ 11,200,000